Bya Cocer Peptides 
ennaku 29 eziyise
EBINTU BYONNNA N’AMAWULIRE GW’EBINTU EBIweereddwa KU MUTINDO GUNO BIKOZESEBWA KU KUSASANYA AMAWULIRE N’EBIKOLWA BY’OKUSOMESA.
Ebintu ebiweereddwa ku mukutu guno bigendereddwamu kunoonyereza mu kisenge (in vitro research) byokka. Okunoonyereza mu vitro (Olulattini: *mu ndabirwamu*, ekitegeeza mu bikozesebwa mu ndabirwamu) kukolebwa ebweru w’omubiri gw’omuntu. Ebintu bino si bya ddagala, tebikkiriziddwa kitongole kya Amerika ekivunaanyizibwa ku by’emmere n’eddagala (FDA), era tebirina kukozesebwa kuziyiza, kujjanjaba oba kuwonya mbeera yonna ya bujjanjabi, bulwadde oba bulwadde. Kikugirwa nnyo mu mateeka okuyingiza ebintu bino mu mubiri gw’omuntu oba ebisolo mu ngeri yonna.
Mu nsi yonna, omugejjo gufuuse ensonga y’ebyobulamu by’abantu eyeeyongera okuba ey’amaanyi, ng’ekwatagana nnyo n’endwadde ez’enjawulo ezitawona ng’endwadde z’emisuwa n’obulwadde bwa sukaali obw’ekika eky’okubiri, ekifudde okunoonya enkola ennungi ez’okugejja ekintu ekikulu mu kunoonyereza kw’abasawo. Survodutide, ng’eddagala eppya, eraga nti liyinza okukola obulungi mu kugejja.
Okulaba ebikwata ku Survodutide
Survodutide ye agonist ekola ebbanga eddene ey’okunoonyereza era mu kiseera kye kimu etunuulira ekirungo kya glucagon-like peptide-1 receptor (GLP-1R) n’ekirungo kya glucose-dependent insulinotropic polypeptide receptor (GIPR). Kyetaaga okuweebwa omulundi gumu gwokka buli wiiki, okuwa abalwadde okunyanguyira okusingawo n’okulongoosa okunywerera ku bujjanjabi obw’ekiseera ekiwanvu.
Enkola ya Survodutide mu kugejja
Okulungamya Enyingiza y’Amaanyi
Okuziyiza okulya: Oluvannyuma lw’okukola GLP-1R ne GIPR, Survodutide ekwatagana n’obusimu obw’omu makkati okulung’amya ekifo ekifuga okulya okulya ekya hypothalamic. Okukola kwa GLP-1R kukola ku vagal afferent fibers okutambuza obubonero eri arcuate nucleus ya hypothalamus, okuziyiza okukola kwa agrep protein (AgRP) neurons, Era esobola okukola proopiomelanocortin (POMC) neurons, bwe kityo ne kireeta okuwulira ng’okkuta n’okukendeeza ku mmere gy’olya. Okukola kwa GIPR era kuyinza okutumbula kino ekiziyiza okwagala okulya okuyita mu makubo g’obusimu agafaanagana oba agakwatagana, bwe kityo ne kikendeeza ku kwagala kw’omubiri emmere n’ekivaamu okukendeeza ku maanyi ge ganywa.
Okukyusa emmere gye yeegomba: Mu nkola ya hamster ey’omugejjo n’obutaba na masavu mu musaayi oguleetebwa emmere ey’eddembe, Survodutide yakola ekikolwa eky’enjawulo ku mmere gye yeegomba. Bw’ogeraageranya n’ekibinja ekifuga, Survodutide yakendeeza nnyo ku kulya emmere erimu amasavu amangi n’amazzi agalimu fructose mu kiseera ky’okujjanjaba ekya wiiki 5, ate nga terina kye yakola ku kulya emmere eya bulijjo n’amazzi aga bulijjo. Enkola eno ey’okulungamya ku kulonda emmere eyamba okukendeeza ku kulya emmere erimu kalori nnyingi, okufuga okukuŋŋaanyizibwa kw’amaanyi agasukkiridde ku nsibuko yaayo n’okuteekawo omusingi gw’okugejja.
Okulungamya ensaasaanya y’amasoboza
Okutumbula oxidation y’amasavu: Survodutide eraga ebikolwa ebinene eby’okulungamya ku nkyukakyuka y’amasavu. Nga ekola GLP-1R ne GIPR, ekwata ku nkyukakyuka y’obutoffaali bw’amasavu okuyita mu makubo agawera agalaga obubonero. Kitumbula lipolysis mu adipocytes, okwongera okufulumya asidi z’amasavu; asidi z’amasavu zino ezifulumizibwa zitambuzibwa mu mitochondria okusobola okukola oxidation, bwe kityo ne kyongera ku nsaasaanya y’amasoboza. Okunoonyereza kulaga nti mu nkola y’amasavu mu kisenge (in vitro adipocyte model), oluvannyuma lw’okujjanjabwa Survodutide, enziyiza enkulu ezenyigira mu lipolysis ne fatty acid oxidation, nga hormone-sensitive lipase (HSL), carnitine palmitoyltransferase-1 (CPT-1), ekiraga nti enkola yaayo ey’okukola mu kutumbula oxidation y’amasavu erimu okulungamya enziyiza enkulu mu nkyukakyuka y’amasavu.
Okwongera ku nsaasaanya y’amaanyi: Ng’oggyeeko okukola butereevu ku butoffaali bw’amasavu okutumbula okukyusakyusa amasavu, Survodutide era eyinza okwongera ku nsaasaanya y’amaanyi ng’ekwata ku nkyukakyuka y’amasoboza mu nkola. Mu kugezesa ebisolo, kyazuulibwa nti wadde ng’emitendera gy’emirimu gy’ebisolo tegyakyuka nnyo oluvannyuma lw’okuweebwa Survodutide, omutindo gwabyo ogw’okukyusakyusa ebiriisa mu musingi gweyongera. Kino kiva ku ngeri eddagala lino gye likola mu bujjuvu ku bitundu n’ebitundu by’omubiri ebingi, okutumbula emirimu gy’okukyusakyusa emmere mu kibumba n’ebinywa by’amagumba, bwe kityo ne kyongera okukozesa amaanyi mu mbeera y’okuwummula n’okutuuka ku bbula ly’amaanyi, ekitumbula okugejja.
Okulungamya enkyukakyuka ya glucose n’okuwulira insulini
Okulongoosa obuziyiza bwa insulini: Abalwadde abagejjulukuka batera okuba n’obuziyiza bwa insulini, ekikosa enkyukakyuka y’amaanyi eya bulijjo n’okukozesa. Survodutide ekola GLP-1R okusitula okufulumya insulini ate nga eyongera ku kuwulira insulini, bwe kityo n’eyongera ku kuddamu kw’omubiri ku insulini. Mu kunoonyereza ku balwadde ba sukaali ow’ekika eky’okubiri, oluvannyuma lwa wiiki 16 nga bajjanjabwa Survodutide, emiwendo gya insulini mu plasma n’omuwendo gw’obuziyiza bwa insulini (HOMA-IR) byakendeera nnyo, ekiraga nti eddagala lino liyinza okulongoosa obuziyiza bwa insulini, okusobozesa obutoffaali okuyingiza obulungi n’okukozesa glucose, okukendeeza ku kukyusibwa kwe okufuuka amasavu, n’okuyamba mu kufuga obuzito.
Okutereeza emiwendo gya glucose mu musaayi: Survodutide’s dual receptor agonist action egiwa enkizo ey’enjawulo mu kulungamya emiwendo gya glucose mu musaayi. GLP-1R gonism etumbula okufulumya insulini ate nga eziyiza okufulumya glucagon, bwe kityo ne kikendeeza ku mutindo gwa glucose mu musaayi. GIPR gonism era etumbula okufulumya insulini mu mbeera z’omubiri. Okuyita mu bikolwa ebikwatagana, esobola bulungi okukuuma omutindo gwa glucose mu musaayi nga gutebenkedde. Ssukaali ateredde mu musaayi ayamba okukendeeza enjala n’okwongera okutereka amaanyi okuva ku nkyukakyuka ya ssukaali mu musaayi, mu ngeri etali ya butereevu ne kikola ekirungi ku kufuga obuzito.
Omulimu gwa Survodutide mu kugejja
Ebikulu ebiva mu kugejja: Mu kugezesebwa okwa randomized, double-blind, placebo-controlled Phase 2 dose-finding trial nga kugenderera abalwadde abagejjulukuka, abantu abakulu 387 ab’emyaka 18–75 nga balina body mass index (BMI) ≥27 kg/m² era tewali ssukaali yagabanyizibwa mu bibinja bitaano mu ngeri ey’ekifuulannenge, nga buli wiiki bafuna empiso za Survodutide (0.6, 2.4, 3.6, oba 4.8 mg) oba placebo wansi w’olususu okumala wiiki 46 ez’obujjanjabi. Ebivuddemu biraga nti mu wiiki 46, abalwadde abajjanjabwa n’eddagala lya Survodutide 4.8 mg baafuna okugejja kwa wakati wa 18.7% bw’ogeraageranya n’ekibinja kya placebo, nga waliwo enjawulo nnene mu kukendeeza ku buzito. Mu kunoonyereza okulala okwali kutunuulidde abalwadde abalina sukaali ow’ekika eky’okubiri n’omugejjo, obujjanjabi bwa Survodutide bwavaamu okugejja okwali kwesigamye ku ddoozi oluvannyuma lwa wiiki 16, ng’okukendeera okusingawo kwa bitundu 8.7%. Okugatta ku ekyo, Survodutide ku ddoozi ya ≥1.8 mg omulundi gumu buli wiiki yaleeta okugejja okusingawo okusinga eddagala erikozesebwa ennyo erya GLP-1 receptor agonist Semaglutid, ekyavaamu okukendeeza ku buzito bwa 5.3%.
Enjawulo mu kikula ky’abantu ne BMI: Okwekenenya okulala mu bibinja ebitonotono kwalaga nti ebikolwa bya Survodutide ku kugejja byawukana mu kikula ky’abantu eky’enjawulo n’emitendera gya BMI. Mu kugezesebwa okwayogeddwako waggulu okwagenderera abalwadde abagejjulukuka, mu wiiki 46, ebitundu by’okugejja ebya wakati (17.0%) mu kibinja kya Survodutide 4.8 mg byali bingi mu bakyala okusinga mu basajja (11.9%); mu bibinja bya BMI eby’enjawulo, abalwadde abalina BMI < 30 kg/m² yalina ebitundu ebinene ennyo eby’okugejja (19.1%), naye emiwendo gy’okugejja egy’enkomeredde tegyali gya njawulo nnyo mu bibinja bya BMI. Kino kiraga nti mu nkola y’obujjanjabi, abasawo basobola okubalirira obulungi ebiva mu Survodutide mu kugejja nga basinziira ku nsonga ng’ekikula ky’omulwadde ne BMI.
Ensaasaanya y’amasavu mu mubiri n’okulongoosa mu nkyukakyuka mu mubiri
Okukendeeza amasavu mu bitundu by’omubiri: Survodutide tekoma ku kukendeeza ku buzito bw’omubiri gwonna wabula era erina akakwate akalungi ku kugabanya amasavu mu mubiri. Okukuŋŋaanyizibwa kw’amasavu mu bitundu by’omubiri ebisusse kukwatagana nnyo n’okukula kw’endwadde ez’enjawulo ezikwata ku nkyukakyuka y’emmere. Mu kunoonyereza okukwatagana, oluvannyuma lw’okufuna obujjanjabi bwa Survodutide okumala ekiseera, abalwadde baafuna okukendeera okw’amaanyi mu kitundu ky’amasavu mu bitundu by’omubiri. Kino kiri bwe kityo kubanga eddagala lino litumbula okumenya n’okufuuka oxidation y’amasavu g’omu bitundu by’omubiri, okulongoosa enkyukakyuka yaago era bwe kityo ne kikendeeza ku bulabe bw’enkyukakyuka y’emmere obukwatagana n’amasavu g’omu bitundu by’omubiri agasukkiridde.
Okulongoosa obuzibu bw’amasavu: Abalwadde abagejjulukuka batera okuba n’amasavu agatali ga bulijjo, gamba nga hypercholesterolemia ne hypertriglyceridemia. Survodutide takoma ku kuyamba mu kugejja wabula era alongoosa ebipimo by’amasavu. Mu kugezesa ebisolo, hamsters ezigejjulukuka ezajjanjabwa ne Survodutide zalaga okukendeera okw’amaanyi mu plasma total cholesterol levels, nga mu kibinja kya Survodutide kyakendeera ebitundu 41% ate mu kibinja kya semaglutide kyakendeera ebitundu 24%. Ebivuddemu ebifaananako bwe bityo byalabibwa mu kugezesebwa kw’abantu, ng’obujjanjabi bwa Survodutide bwavaako okukendeera okw’amaanyi mu miwendo gya triglyceride. Era yakola diguli ez’enjawulo ez’ebikolwa eby’okulungamya ku kolesterol ow’amasavu amatono (LDL-C) ne kolesterol ow’amasavu amangi (HDL-C), ekyayamba okutereeza obuzibu bw’amasavu mu musaayi n’okukendeeza ku bulabe bw’endwadde z’emisuwa.
Ebikosa ensonga z’obulabe eri emisuwa n’emisuwa
Okukendeeza puleesa: Omugejjo kye kimu ku bintu ebikulu ebiyinza okuvaako puleesa. Mu kugezesebwa okw’obujjanjabi okwagenderera abalwadde abagejjulukuka, oluvannyuma lwa wiiki 46 nga bajjanjabwa Survodutide, puleesa zombi eza systolic blood pressure (SBP) ne diastolic blood pressure (DBP) zalaga okukendeera okw’amaanyi. Bw’ogeraageranya n’ekibinja kya placebo, ekibinja kya Survodutide ekya 4.8 mg kyalaga okukendeera okusinga obunene okwa wakati wa mmHg 10.2 mu SBP ne mmHg 4.8 mu DBP. Kino ekikendeeza puleesa kiyinza okuba nga kyekuusa ku bintu ebingi, omuli Survodutide okulongoosa enkola y’emisuwa endothelial, okukendeeza ku mirimu gy’obusimu obusaasira, n’okugejja, nga byonna awamu biyamba okukendeeza ku bulabe bw’endwadde z’emisuwa.
Okulongoosa enkola y’emisuwa: Survodutide era eyinza okukola ebikolwa eby’obukuumi ku nkola y’emisuwa n’emisuwa ng’elongoosa enkola y’obutoffaali bw’emisuwa. Oluvannyuma lw’okuweebwa Survodutide, okufulumya nitric oxide (NO) okuva mu butoffaali bw’emisuwa endothelial kweyongera. NO kirungo kikulu ekigaziya emisuwa, ekikendeeza ku buziyiza bw’emisuwa, n’okulongoosa entambula y’omusaayi. Eddagala lino era liyinza okuziyiza okuddamu kw’okuzimba n’okunyigirizibwa okw’okwokya, bwe kityo ne kikendeeza ku kwonooneka kw’ekisenge ky’emisuwa n’okwongera okukuuma obulamu bw’emisuwa.
Okusiiga eddagala lya Survodutide mu kugejja
Omuwendo gw’abantu ogugendereddwamu
Abantu abagejjulukuka n’abagejjulukuka: Ku bantu abagejjulukuka oba abagejjulukuka ennyo nga balina BMI ≥ 27 kg/m², Survodutide eraga nti ekola bulungi mu kugejja. Abalwadde bombi abagejjulukuka ennyangu n’abo abalina omugejjo nga bawerekerwako obuzibu obulala mu nkyukakyuka y’emmere nga sukaali ow’ekika eky’okubiri oba dyslipidemia bayinza okuganyulwa mu bujjanjabi bwa Survodutide. Mu kugezesebwa okw’obujjanjabi, abalwadde abagejjulukuka mu bibinja by’emyaka egy’enjawulo (emyaka 18–75) baalaga okuddamu okulungi eri Survodutide, ekiraga nti abantu bangi abalina ebisaanyizo.
Abalwadde abagejjulukuka nga beekuusa ku ndwadde ezenjawulo: Ng’oggyeeko abantu abagejjulukuka okutwalira awamu, Survodutide era nkola ya bujjanjabi eri omugejjo oguva ku ndwadde ezenjawulo, gamba nga polycystic ovary syndrome (PCOS), omugejjo n’obuzibu mu nkyukakyuka y’emmere gye bitera okubeera awamu.
Okwongera okutumbula ebikolwa by’okugejja n’okulongoosa embeera y’omubiri, Survodutide esobola okukozesebwa ng’egatta wamu n’enkola endala ez’obujjanjabi. Bwe bigattibwa wamu n‟okuyingira mu bulamu (okufuga emmere n‟okukola dduyiro), ebikosa okukwatagana bisobola okutuukibwako. Mu kugezesebwa mu malwaliro, abalwadde abaafuna obujjanjabi bwa Survodutide nga bwegatta ne dduyiro owa bulijjo n’emmere ennungi baafuna okugejja okusingawo n’okulongoosa okw’amaanyi mu bubonero bw’enkyukakyuka y’emmere. Okugatta ku ekyo, eri abalwadde ba sukaali ow’ekika eky’okubiri n’omugejjo, Survodutide esobola okukozesebwa ng’egatta wamu n’eddagala eddala eriweweeza ku ssukaali nga metformin okufuga ssukaali mu musaayi ate ng’otuuka ku kuddukanya obulungi obuzito.
Mu bufunzi
Mu bufunze, Survodutide, nga novel dual receptor agonist, ya mugaso mu kugejja. Enkola yaayo ey’enjawulo ey’okukola tekoma ku kukendeeza bulungi buzito wabula era etereeza ensaasaanya y’amasavu mu mubiri, etereeza enkyukakyuka ya glucose n’amasavu, n’okukendeeza ku bulabe bw’emisuwa.
Ensonda
[1] Briand F, Augustin R, Bleymehl K, n’abalala. 7279 Survodutide ne Semaglutid Zombi Zireetera Okugejja naye Ziraga Ebikosa Eby’enjawulo ku Emmere Okwettanira n’Okukendeera kw’Amasavu mu Free Choice Diet-induced Obese Hamster Model[J]. Journal of the Endocrine Society, 2024,8 (Supplement_1): bvae134-bvae163.DOI: 10.1210 / jendso / bvae163.034.
[2] Le Roux C, Steen O, Lucas K. J., n’abalala. Survodutide, glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist, erongoosa cardiometabolic parameters mu bantu abakulu abalina omugejjo: okwekenneenya okugezesebwa kwa placebo-controlled, randomized phase 2 trial[J]. Ekitabo ky’omutima ekya Bulaaya, 2024,45 (Supplement_1):ehae666-ehae2895.DOI:10.1093/eurheartj/ehae666.2895.
[3] Blüher M, Rosenstock J, Hoefler J, n’abalala. Ebikosa ddoozi-okuddamu ku HbA (1c) n’okukendeeza ku buzito bw’omubiri obwa survodutide, eddagala eriziyiza glucagon/GLP-1 ery’emirundi ebiri, bw’ogeraageranya ne placebo ne open-label semaglutide mu bantu abalina ssukaali ow’ekika eky’okubiri: okugezesebwa okw’obujjanjabi okutali kwa bulijjo[J]. Obulwadde bwa sukaali, 2024, 67 (3): 470-482.DOI: 10.1007 / s00125-023-06053-9.
[4] Mei Z, Pu J, Shao Z. Okugezesebwa kubiri okw’obujjanjabi bwa MASH n’obulwadde bw’ekibumba[J]. New England Journal of Eddagala, 2024,391 (15): 1461-1462.DOI: 10.1056 / NEJMc2411003.
[5] Sanyal A. J., Bedossa P., Fraessdorf M., n’abalala. Okugezesebwa okw’omutendera ogw’okubiri okwa Survodutide mu MASH ne Fibrosis[J]. New England Journal of Eddagala, 2024,391 (4): 311-319.DOI: 10.1056 / NEJMoa2401755.
[6] Le Roux CW, Steen O, Lucas K. J., n’abalala. Glucagon ne GLP-1 receptor dual agonist survodutide ku mugejjo: okugezesebwa okwa randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.[J]. Ekitabo ekiyitibwa Lancet. Ssukaali & Endocrinology, 2024. Enkola y’okukuuma obutonde bw’ensi mu bitundu by’eggwanga eby’enjawulo
[7] Lawitz E. J., Fraessdorf M., Neff G. W., n’abalala. OS-119 Survodutide (BI 456906), glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, mu bantu abalina obulwadde bwa cirrhosis obuliyirirwa n’obutasaliddwa: okugezesebwa okw’amawanga amangi, okuggule, omutendera 1[J]. Ekitabo ky’eby’ekibumba, 2024. https://api.semanticscholar.org/CorpusID:270457365
[8] Le Roux CW, Steen O, Lucas K. J., n’abalala. 6926 Okwekenenya ebibinja ebitonotono okusinziira ku kikula ky’omuntu n’omuwendo gw’omubiri (BMI) mu bantu ababeera n’omugejjo/omugejjo mu Survodutide, a Glucagon/GLP-1 Receptor Dual Agonist, Phase II Trial[J]. Journal of the Endocrine Society, 2024,8 (Supplement_1): bvae133-bvae163.DOI: 10.1210 / jendso / bvae163.033.
Ekintu ekiriwo okukozesebwa mu kunoonyereza kwokka:
